<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850406</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-007</org_study_id>
    <nct_id>NCT02850406</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of GBT440 in Adolescents With Sickle Cell Disease</brief_title>
  <official_title>A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Adolescents With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of two parts, Part A and Part B. Part A is a single dose PK study in
      adolescent subjects with Sickle Cell Disease. Part B is a multiple dose safety, exploratory
      efficacy and PK study in adolescent Sickle Cell Disease subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic profile of GBT440 including maximum concentration</measure>
    <time_frame>Pre-dose to Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic profile of GBT440 including the time taken to reach the maximum concentration</measure>
    <time_frame>Pre-dose to Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic profile of GBT440 including the total drug concentration over time</measure>
    <time_frame>Pre-dose to Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Days 1 - 58</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Days 1 - 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B Multiple Dose effect on Laboratory Biomarkers of Hemolysis</measure>
    <time_frame>Days 1 - 58</time_frame>
    <description>To evaluate the effect of GBT440 on clinical laboratory biomarkers of hemolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetic profile of GBT440 including maximum concentration</measure>
    <time_frame>Pre-dose to Day 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetic profile of GBT440 including the time taken to reach the maximum concentration</measure>
    <time_frame>Pre-dose to Day 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetic profile of GBT440 including the total drug concentration over time</measure>
    <time_frame>Pre-dose to Day 58</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>GBT440</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects to receive daily oral dosing of GBT440 for 1 day (single dose) or up to 28 days (multiple dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GBT440</intervention_name>
    <description>GBT440 will be administered as oral capsules</description>
    <arm_group_label>GBT440</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female age 12 to 17 years of age (inclusive) with homozygous hemoglobin SS
             (HbSS) or hemoglobin S beta0 thalassemia (HbS β0 thal).

          2. A subject taking hydroxyurea may be enrolled if the dose has been stable for at least
             3 months with no anticipated need for dose adjustments during the study and no sign
             of hematological toxicity.

          3. Written informed parental/ guardian consent and subject assent has been obtained per
             institutional review board (IRB)/Ethics Committee (EC) policy and requirements,
             consistent with International Council on Harmonisation (ICH) guidelines.

        Exclusion Criteria:

          1. Any one of the following requiring medical attention within 14 days prior to signing
             the informed consent form (ICF):

               -  Vaso-occlusive crisis (VOC)

               -  Acute chest syndrome (ACS)

               -  Stroke

               -  Splenic sequestration crisis

               -  Dactylitis

          2. Requires chronic transfusion therapy

          3. History of stroke or meeting criteria for primary stroke prophylaxis (history of two
             Transcranial Doppler (TCD) measurements ≥ 200 cm/sec)

          4. Transfusion within 30 days prior to signing the Informed Consent Form.

          5. Renal dysfunction requiring chronic dialysis or creatinine ≥ 1.5 milligrams per
             deciliter (mg/dL)

          6. History of hepatic compromise or severe liver disease

          7. Clinically relevant cardiac abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ganesh Balaratnam, MBChB BAO (NUI)</last_name>
    <role>Study Director</role>
    <affiliation>Global Blood Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ganesh Balaratnam, MBChB BAO (NUI)</last_name>
    <phone>650-741-7700</phone>
    <email>GBalaratnam@globalbloodtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Utzelmann</last_name>
      <phone>901-595-6216</phone>
      <email>Bettina.Utzelmann@stjude.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 27, 2016</lastchanged_date>
  <firstreceived_date>July 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
